Kidney Therapy Articles & Analysis
58 news found
Consistent with previous data indicating various benefits of rivaroxaban over VKAs on kidney outcomes, XARENO also revealed that Xarelto was associated with a reduced risk of progression to CKD stage 5 or the initiation of chronic kidney replacement therapy. ...
ByBayer AG
“Kerendia addresses a key cause of disease progression that is not addressed by other therapies, and offers physicians a distinct path to protect patients from further kidney damage and cardiovascular events. ...
ByBayer AG
About Chronic Kidney Disease in Type 2 Diabetes Chronic kidney disease (CKD) is a common and potentially deadly condition that is widely underrecognized. ...
ByBayer AG
Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that ApolloMed received certification from the National Committee for Quality Assurance ("NCQA") for ...
EchoPixel has once again contributed to a pioneering procedure at CentraCare – St. Cloud Hospital with the first team to remove a heart tumor without invasive open heart surgery using the novel AlphaVac catheter. Previously CentraCare had been the first to use EchoPixel’s 4D hologram technology to conduct the WATCHMAN implant, which is a one-time, minimally invasive procedure ...
This data will include new post-hoc analyses of FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, as well as the design of the Phase II CONFIDENCE study, investigating simultaneous initial combination therapy with finerenone and an SGLT2-inhibitor in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). ...
ByBayer AG
In November 2021, Bayer announced the initiation of FIONA, a multicenter, randomized, double-blind, placebo-controlled Phase III study, to investigate the efficacy, safety, and pharmacokinetics/pharmacodynamics (PK/PD) of finerenone, in addition to standard of care, in approximately 200 pediatric patients with chronic kidney disease (CKD) and severely increased proteinuria. In ...
ByBayer AG
Quanta Dialysis Technologies Inc (“Quanta or “The Company”), a medical technology company committed to making kidney care more accessible with its SC+ hemodialysis system, announced today that CEO John E. Milad will leave the company effective July 15, 2022. The company has begun the search for a new CEO. Upon Milad’s departure and until the appointment of a new CEO, ...
In November 2021, Bayer announced the initiation of FIONA, a multicenter, randomized, double-blind, placebo-controlled Phase III study, to investigate the efficacy, safety and pharmacokinetics/pharmacodynamics (PK/PD) of finerenone, in addition to standard of care, in approximately 200 pediatric patients with chronic kidney disease (CKD) and severely increased proteinuria. In ...
ByBayer AG
Prof. M.S Sandhu from PGIMER Chandigarh #Radiology Department – India. recently gave an interview in which he illustrated the peculiarities of automatic CO2 angiography. In this interview, Prof. Sandhu remarked the Angiodroid technology. Here is a brief excerpt: “A recently developed injector with a very novel method to map these vessels is to use carbon dioxide as a ...
(Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary, blinded data from an ongoing Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, for the treatment of BK viremia (BKV) in adult kidney transplant recipients. These data from the largest ...
ByKalaris
“These results demonstrated that patients on long-term voclosporin therapy continue to experience clinically relevant benefits, including significant preservation of kidney function long-term, with no unexpected, new safety ...
Improvements in kidney size, function, and renal matrix remodeling, with corresponding gene expression were noted with both doses of 0.3 mg/kg and 3 mg/kg of INV-202”, said Dr. ...
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the first participant has been dosed in a Phase 1 Study of VEL-101/FR104 [NCT05238493], a study sponsored and conducted by its partner in transplantation, Veloxis Pharmaceuticals, Inc., an Asahi Kasei company. VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention ...
If poorly controlled, LN can lead to permanent and irreversible tissue damage within the kidney, resulting in kidney failure. Black and Asian individuals with SLE are four times more likely to develop LN and individuals of Hispanic ancestry are approximately twice as likely to develop the disease when compared with Caucasian individuals. ...
Two compassionate use case reports of posoleucel therapy for refractory disseminated AdV infection post allo-HCT were presented at the 2022 Tandem Meetings |Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant ...
ByKalaris
(Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KALM-1 and KALM-2 clinical trials evaluating KORSUVA™ (difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus in patients undergoing ...
TX200 is composed of autologous Treg cells engineered to express an HLA-A2 CAR. This investigational cell therapy is being assessed in HLA-A2 negative patients receiving a mismatched HLA-A2 positive kidney from a living donor. ...
The approval of finerenone offers a new path to protect patients from further kidney and cardiovascular damage through addressing MR overactivation, a key driver of CKD progression, which is unaddressed by currently available ...
ByBayer AG
QUANTA Dialysis Technologies Ltd (“QUANTA” or the “Company”), a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, has released a new report that suggests people with kidney failure who wish to do home dialysis face unequal access across the UK. The Bridging the Gap report finds that failure to offer such treatment ...